Editas Medicine, Inc. (EDIT) bonds
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.14−0.24 (-10.08%)
Close on Nov 12, 2026Market cap $328.66MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$56.82M
$7.50M due within a year
Net debt
-$36.35M
After $93.17M of cash
Implied interest rate
3.67%
FY2025 interest ÷ average debt
Interest coverage
-75.2×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Editas Medicine's 10-K for the period ended Dec 31, 2025
| Issue | Coupon |
|---|---|
| Promissory Notes | 4.80% |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
See a number that looks wrong?